Welcome to our dedicated page for Alzamend Neuro SEC filings (Ticker: ALZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alzamend Neuro, Inc. files regulatory reports that document its status as a Nasdaq-listed clinical-stage biopharmaceutical company and emerging growth company. Recent disclosures cover common stock registered on The Nasdaq Capital Market, annual meeting and proxy matters, stockholder voting results, and board and governance records.
The company's filings also describe capital-structure activity, including at-the-market offering documents, unregistered common stock issuances tied to convertible preferred stock, elimination of Series B and Series C preferred stock designations, and Nasdaq continued-listing compliance matters. These records frame ALZN's financing, governance and public-company reporting obligations around its neurodegenerative and psychiatric-disorder development programs.
Alzamend Neuro, Inc. (ALZN) reported a net loss of $3.0 million for the three months ended July 31, 2026, slightly higher than the $2.7 million loss a year earlier, and it continues to generate no product revenue as its two drug candidates, AL001 and ALZN002, remain in clinical development.
Cash increased to $7.6 million from $0.7 million at April 30, 2026, driven by a $7.5 million first tranche of Series D Convertible Preferred Stock sold to Ault Lending and $0.7 million raised via an at-the-market common stock program, lifting stockholders’ equity to $5.8 million. Research and development expense declined 38% to $1.1 million as an earlier imaging study concluded, while general and administrative expense more than doubled to $1.9 million, largely on higher legal and professional fees. The company ended the quarter with working capital of $5.5 million but disclosed an accumulated deficit of $70.3 million, stated it expects continued losses, and concluded that these conditions raise substantial doubt about its ability to continue as a going concern, noting that additional financing will be required to sustain operations and advance its clinical programs.
Alzamend Neuro, Inc. (ALZN) director Milton C. Ault III reported selling 2,000 shares of common stock in open-market transactions on August 26, 2026 at a volume weighted average price of $1.5581 per share, reducing his directly held shares to 0. He continues to report indirect ownership of Alzamend Neuro common stock, including shares held through Ault Lending, LLC, Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC. Ault calculated a short-swing profit on matchable transactions that he intends to disgorge to Alzamend Neuro under Section 16(b) of the Exchange Act.
Alzamend Neuro, Inc. (ALZN) had an amended insider report from director Milton C. Ault III correcting previously omitted purchases on April 14, 2026. An entity associated with him, Ault Lending, LLC, bought 108,388 shares of common stock at about $1.0047 per share, held indirectly, bringing that entity’s holdings to 116,648 shares. Ault also directly purchased 2,000 shares at a volume weighted average price of $1.0338 per share, with trading that day occurring between $1.00 and $1.05 per share. He is also reported to have indirect holdings of 11,068 shares through Ault Life Sciences, Inc. and 61 shares through Ault Life Sciences Fund, LLC.
Alzamend Neuro, Inc. (ALZN) director Milton C. Ault III reported additional purchases of common stock on April 14, 2026 in an amended Form 4. An affiliated entity, Ault Lending, LLC, bought 108,388 shares at $1.0047 per share, and Ault personally bought 2,000 shares with a volume weighted average price of $1.0338, in open market transactions. Following these transactions, reported holdings include 116,648 indirect shares via Ault Lending, 11,068 indirect shares via Ault Life Sciences, Inc., 61 indirect shares via Ault Life Sciences Fund, LLC, and 2,000 direct shares.
Alzamend Neuro, Inc. (ALZN) is calling a virtual 2027 annual stockholders’ meeting on October 19, 2026 to elect six directors, ratify Haskell & White LLP as auditor for the year ending April 30, 2027, approve a key financing-related conversion proposal, and approve potential adjournments if more time is needed to gather votes.
The central item is approval under Nasdaq Rule 5635 of the conversion of up to $25 million of Series D Preferred Stock held by affiliate Ault Lending, LLC into common stock. The SPA provides for a $7.5 million initial tranche, a $2.5 million second tranche, then $1.0 million monthly purchases until the full $25 million is funded, subject to closing conditions. Conversion uses a variable price formula with a floor tied to market prices and a cap of $2.00 per share, and is currently capped at 19.99% of pre-deal common shares outstanding unless stockholders approve additional issuances. The company states this financing is important to help satisfy Nasdaq’s $2,500,000 stockholders’ equity requirement by September 16, 2026. The proxy also notes a temporary shortfall in Nasdaq’s independent director requirement following a director’s death, which must be cured by January 18, 2027.
Alzamend Neuro, Inc. (symbol: ALZN) is the issuer of record for a Form S-1 filing submitted to the SEC.
Alzamend Neuro, Inc. (symbol: ALZN) is the issuer of record for a Form 4/A filing submitted to the SEC.
Alzamend Neuro, Inc. (ALZN) received an amended initial ownership report on Form 3/A that does not reflect new transactions but clarifies who is a reporting person under Section 16. The amendment adds Hyperscale Data, Inc. (HSD), Ault Capital Group, Inc. (ACG), and Ault Lending, LLC as reporting persons, each as a "Director by deputization" based on their representation on the board. The filing lists indirect holdings of Common Stock Purchase Warrants held of record by Ault Lending, with Mr. Ault, Executive Chairman of HSD, deemed to have voting and investment power over these securities.
Hyperscale Data, Inc., a director-by-deputization of Alzamend Neuro, Inc., reported that its indirectly controlled subsidiary Ault Lending, LLC received a grant of 7,500 shares of Alzamend’s Series D Convertible Preferred Stock on July 31, 2026 at a reported price of $1,000.00 per share, resulting in indirect holdings of 7,500 preferred shares.
Each Series D share has a stated value of $1,050.00 and is convertible into common stock at a variable Conversion Price. As of August 4, 2026, the Conversion Price was $1.016 per share, so each preferred share was then convertible into approximately 1,033.5 common shares. The filing also lists several existing common stock purchase warrants held indirectly through Ault Lending.
Hyperscale Data, Inc., whose Executive Chairman is Milton C. Ault III, reports indirect ownership in Alzamend Neuro through its wholly owned subsidiary Ault Lending. It lists common stock purchase warrants exercisable into 494.0000, 988.0000, 13556.0000, 8667.0000 and 1111.0000 common shares at exercise prices of 4050.0000 and 108.0000, with expirations between 2026 and 2029. HSD and related entities are treated as directors by deputization for Section 16 purposes.